Overview

Rapid Hepatitis C Elimination Trial- A Pilot Study of Daclatasvir/Asunaprevir/BMS-791325 With or Without Ribavirin To Treat Hepatitis C Virus

Status:
Completed

Trial end date:
2016-02-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine whether treatment with Daclatasvir/Asunaprevir/BMS-791325, with or without ribavirin, for 8, 6, or 4 weeks is feasible for the treatment of genotype 1a chronic hepatitis C in patients without cirrhosis.

Phase:

N/A

Details

Lead Sponsor:

Timothy Morgan, MD

Collaborators:

Bristol-Myers Squibb
National Cancer Institute (NCI)
VA Long Beach Healthcare System

Treatments:

Asunaprevir
Ribavirin